ESSEX BIO-TECH: The biological product license application for the anti-VEGF ophthalmic injection (HLX04-O) for the treatment of wet AMD has been accepted
I'm PortAI, I can summarize articles.
ESSEX BIO-TECH announced that its biologics license application for the anti-VEGF ophthalmic injection biologic (HLX04-O) for the treatment of wet AMD has been accepted by the National Medical Products Administration of China. This product is co-developed by the company's wholly-owned subsidiary and HENLIUS, optimized based on HENLIUS's Hanbeitai, aiming to meet the needs of ophthalmic medications. The Phase III clinical study of HLX04-O is being conducted in China and several other countries, with completion expected in 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments